According to the FLAURA study, advanced EGFR-mutant NSCLC patients receiving the third-generation EGFR-TKI osimertinib as first-line treatment could experience a significantly longer median PFS [18.9 months versus 10.2 months; HR of 0.46 (95% CI, 0.37 to 0.57); p < 0.001] as well as a longer median OS [38.6 months versus 31.8 months; HR of 0.80 (95% CI, 0.64 to 1.00); p = 0.046] compared to patients given first-generation EGFR-TKIs [10,11]. Here, EGFR is linked to non-small cell lung carcinoma.